Supernus Pharmaceuticals has delivered a 75.7% gain over the past three years, even though the stock is down year to date, which naturally puts the current share price under the microscope. The immediate question for you as an investor is whether that price is still grounded in what the business is actually generating in sales. The 75.7% return over three years puts real weight on the question of whether Supernus Pharmaceuticals' current valuation can still be explained by its revenue...
Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus Pharmaceuticals. The share price closed at $41.92 after a 7 day share price return of 2.34%, yet the 90 day share price return declined 10.64% and the 1 year total shareholder return fell 26.46%. However,...
Supernus Pharmaceuticals (NasdaqGM:SUPN) has completed its merger of equals with Indivior Pharmaceuticals, forming a combined specialty pharma business. As part of the transaction, Supernus shares have been delisted from Nasdaq, with equity now rolling into the new merged entity. The deal includes consolidation of corporate structures and leadership roles, with governance now housed under a single combined board and executive team. The completion of the Supernus and Indivior merger and...
Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunitiesCombined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol
Motley Fool Press Release.
Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.
Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...
Indivior Pharmaceuticals (INDV) said Thursday that its board of directors has declared a special cas
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Wednesday, September 9, 2026Fireside chat: 2:45 p.m. ETPlace: Waldorf Astoria, New York, NYWebcast Link: Here Wells Fargo Hea
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a...
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
This is the newest page. Registered accounts read further back.